IVI in the Media

Maeil Business Newspaper | All music is beautiful in its own way, but Violinist Sang Hee Lee’s music shines a special light

Nature | Six months of COVID vaccines: what 1.7 billion doses have taught scientists

Asian Boss | We Asked Top Vaccine Expert About COVID Vaccine Problems

Bloomberg | Consequences of ‘Huge’ Global Gap in Vaccinations

EIU Perspectives | What does Denmark’s permanent suspension of both the AstraZeneca and Janssen covid-19 vaccines mean for other countries?

Asia Times | Vaccinations in a race against viral variants

Nature | Why COVID vaccines are so difficult to compare

DEVEX | Opinion: COVAX — too big, and too important, to fail

CNN | “Our response needs to be clear, strong, and unified”

South China Morning Post | Coronavirus vaccines will save 2021? Not so fast, here’s what the experts think

Bloomberg | Will the Covid-19 Vaccines Be Effective and Safe?

Asian Boss | Update On COVID-19 Vaccine Price & Schedule From A Leading Vaccine Expert

The Telegraph | ‘If you are not prepared, the virus has found every weakness’: How countries in Asia tamed Covid-19

CGTN | ‘The vaccine itself is not the silver bullet,’ says International Vaccine Institute

Devex | Q&A: Why Jerome Kim is ‘hopeful’ but cautious about distributing a COVID-19 vaccine

Maeil Business Newspaper | IVI Director General Jerome Kim Shares His Thoughts on Resurgence of COVID-19 Outbreaks in S. Korea

Chosun Ilbo | IVI Director General Jerome Kim Shares His Thoughts on Equitable Access of COVID-19 Vaccines

Channel News Asia | On a fast track like never before: The COVID-19 vaccine effort and 5 vital questions

The Economist’s Future of Healthcare Insight Hour | Vaccine development: A race to the finish line

Devex | Q&A: Is COVID-19 helping or hindering progress toward an HIV vaccine?

TED | The trials, tribulations and timeline of a COVID-19 vaccine

Wired Korea | The End of World War C: Peace without Victory?

Asian Boss | World’s Leading Vaccine Expert Fact-Checks COVID-19 Vaccine Conspiracy

Development Today | Why Sweden funds a vaccine institute in Korea and not Oslo-based CEPI

CNBC | Parts of Asia that relaxed restrictions without a resurgence in coronavirus cases did these three things

The Korea Herald | [Herald Interview] ‘Making vaccines accessible is biggest COVID-19 challenge’

CGTN: The Agenda with Stephen Cole | Speed of vaccine trials is ‘unprecedented’

Asian Boss | We Asked The World’s Leading Vaccine Expert About COVID-19 Vaccine

The Guardian | Test, trace, contain: how South Korea flattened its coronavirus curve

BBC World Service: The Inquiry | How do we come out of the lockdown? (13:00)

ANC 24/7 | Int’l Vaccine Institute: 12-18 months reasonable timetable for development of Covid-19 vaccine

Seeker | How Fast Can We Make a Coronavirus Vaccine?

Education City Speaker Series: Flattening the Curve – Global Responses to COVID-19

Wion News | About 70% of vaccines used around the world are made in India: S Korean expert Dr Jerome Kim

South China Morning Post | How long will a coronavirus vaccine take? A Q&A with Jerome Kim, head of the International Vaccine Institute

BBC World News | Jerome Kim: Vaccines are the long-term solution to the pandemic

The Korea Times | Developing vaccine against COVID-19

TRT: Bigger than Five | COVID-19: The World Reacts

South Korea’s fight against coronavirus (CBS News)

NDTV | Top South Korea Doctor On Why He Thinks Coronavirus Is Not A ‘Chinese Virus’

RTE | What South Korea can teach Ireland about fighting Covid-19

Physical distancing should last months, not weeks, says epidemiologist (Yahoo News Canada)

Development of vaccine requires massive investment… international cooperation is needed (Korea Economic Daily)

COVID-19 Pandemic (Arirang TV, 22:50~46:00)

By then, we’ll have a vaccine on our side (Hankyoreh—Korean)

Coronavirus Pandemic: International Vaccine Institute director on how long it will take to develop vaccine (CGTN)

Testing times: Why South Korea’s COVID-19 strategy is working (Al Jazeera English)

Genexine seeks to compress the vaccine timeline

Genexine, Binex to develop COVID-19 vaccine (Korea Biomedical Review)

Genexine, Binex to co-develop coronavirus vaccine GX-19 (Korea Herald)

How close are we to a COVID-19 vaccine? Jerome H. Kim from International Vaccine Institute (Arirang News)

COVID-19 vaccine, drugs on fast track for development: IVI chief (Yonhap News)

Inside the race to find a coronavirus vaccine (Devex)

Chinese students keen for turnaround (China Daily)

China Daily | S. Korea can try out makeshift hospitals, experts say

Director General Jerome Kim for Phoenix TV

Speed and accuracy vital for COVID-19 test kits (Arirang News)

2020 COVID-19 Live Updates: Jerome Kim for tbs eFM

Jerome Kim for KBS WORLD Radio, Korea24 on the COVID-19 outbreak in South Korea

Korea should join efforts in vaccine development to prevent pandemics (JoongAng Ilbo)

Future global health threats

IVI: COVID-19 could linger (Korean)

Jerome Kim for Korea, Factual: “Hong Kong’s handling of COVID-19 outbreak & Prospects of vaccine development”

Concerns about the spread of COVID-19: When will a vaccine be developed? When can we expect the “Super Vaccine”?

Al Jazeera English | Scientists call for global cooperation over coronavirus

When will COVID-19 vaccine be commercialized…And “super vaccine”? (Korean)

Global push to find vaccine against devastating bug growing

IVI receives $15.7 million to conduct Ph III trials of typhoid vaccine

Korean vaccines expanding global territory

Neglected Victims of Neglected Diseases

Let’s build a common defense against epidemics

Vaccine investment brings 16-fold return… partnering with Bill Gates

World must join forces to prevent infectious diseases

IVI editorial in The Korea Herald advocates for Korean leadership for global health

×

KNIH, IVI sign MOU on research cooperation

Author
Hong
Date
2012-07-27 00:00
Views
6402
 
Korea National Institute of Health and IVI sign MOU on research collaboration

 

Seoul, July 20, 2012—The Korea National Institute of Health (KNIH, Director-General Dr. Cho Myeong-chan) and the International Vaccine Institute (IVI, Director-General Christian Loucq) exchanged a memorandum of understanding to expedite research and development of vaccines for public use at IVI headquarters on July 20.

 

The two organizations have jointly conducted a project to develop technology for long-term storage of vaccines, and will expand joint research and development, cooperation, and exchange.

 

According to the MOU,  the two organizations will boost research cooperation in vaccine development, and strengthen and expand cooperation in diverse fields of interest, including:

  • Development of vaccines against emerging or re-emerging infectious diseases with a public health purpose;
  • Molecular epidemiological studies for vaccine development;
  • Sharing information and resources in the field of emerging and re-emerging infectious diseases.

The two sides will also cooperate in the following areas:

  • Cooperative scientific programs and research projects, and
  • Exchanges and training of scientists and delegations.

The two organizations expect strengthened cooperation between the two sides will generate synergistic effect in the field of vaccine R&D, and thus enable them to emerge as global centers of research, including in the development of next-generation vaccines.

 

KNIH is responsible for research on infectious diseases and chronic illnesses that require management by the state. The Institute is focusing on vaccines against smallpox, anthrax, avian influenza, and hand, foot and mouth disease.

 

Meanwhile, IVI is the first international organization headquartered in Korea, and is hosted by the Korean government. The Institute is endeavoring to combat infectious diseases through research and development, clinical trials of vaccines, and vaccine assistance programs for developing countries with support from the Korean government and the Bill and Melinda Gates Foundation, among others.

 

Left to right: Dr. Christian Loucq, IVI Director-General; His Excellency Dr. Chemin Rim, Minister of Health and Welfare; and Dr. Myeong-chan Cho, Director General of KNIH at IVI headquarters in Seoul after the MOU signing ceremony between IVI and KNIH.

KNIH Director-General Dr. Cho Myeong-chan said, “We will step up research in the vaccine field by engaging in far-reaching exchange with IVI, in order to consolidate the foundation to protect the health and safety of the people from infectious diseases.”

 

IVI Director-General Dr. Christian Loucq added, “IVI is very pleased to collaborate with KNIH on vaccine research projects and training initiatives, which will mutually benefit the two organizations as well as Korea’s vaccine R&D. More importantly, this collaboration will ultimately contribute to improving the health and well-being of people in Korea and worldwide.”

DONATE